Literature DB >> 26629279

Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma.

Lisa Raedler.   

Abstract

Entities:  

Year:  2015        PMID： 26629279      PMCID： PMC4665054     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  4 in total

Review 1.  Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.

Authors:  Karin E Smedby; Henrik Hjalgrim
Journal:  Semin Cancer Biol       Date:  2011-09-18       Impact factor: 15.707

2.  A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

Authors:  Maria T Petrucci; Pilar Giraldo; Paolo Corradini; Adriana Teixeira; Meletios A Dimopoulos; Igor W Blau; Johannes Drach; Ralf Angermund; Nathalie Allietta; Esther Broer; Vivien Mitchell; Joan Bladé
Journal:  Br J Haematol       Date:  2013-01-07       Impact factor: 6.998

3.  Economic burden of metastatic bone disease in the U.S.

Authors:  Kathy L Schulman; Joseph Kohles
Journal:  Cancer       Date:  2007-06-01       Impact factor: 6.860

Review 4.  New strategies in the treatment of multiple myeloma.

Authors:  Nikhil C Munshi; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2013-03-20       Impact factor: 12.531
  4 in total
  21 in total

1.  Emerging Cancer Therapeutic Targets in Protein Homeostasis.

Authors:  Prabhakar Bastola; Derek B Oien; Megan Cooley; Jeremy Chien
Journal:  AAPS J       Date:  2018-08-27       Impact factor: 4.009

Review 2.  Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.

Authors:  Natura Myeku; Karen E Duff
Journal:  Trends Mol Med       Date:  2017-12-09       Impact factor: 11.951

3.  Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.

Authors:  Lucy Swift; Aarthi Jayanthan; Yibing Ruan; Ronald Anderson; Jessica Boklan; Tanya Trippett; Aru Narendran
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

Review 4.  Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies.

Authors:  Jolan E Walter; Jocelyn R Farmer; Zsofia Foldvari; Troy R Torgerson; Megan A Cooper
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Nov - Dec

Review 5.  The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.

Authors:  Richard Arkwright; Tri Minh Pham; Jeffrey A Zonder; Q Ping Dou
Journal:  Expert Opin Drug Discov       Date:  2016-12-20       Impact factor: 6.098

6.  Combination Therapy of an Antibody Specific for Transferrin Receptor 1 (ch128.1/IgG1) With Bortezomib or Lenalidomide Results in Increased Survival in an In Vivo Model of Human Multiple Myeloma: A Brief Communication.

Authors:  Pierre V Candelaria; Miguel Nava; Otoniel Martínez-Maza; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  J Immunother       Date:  2022-04-26       Impact factor: 4.912

Review 7.  Unfolded Protein Response in Leukemia: From Basic Understanding to Therapeutic Opportunities.

Authors:  Ali Khateb; Ze'ev A Ronai
Journal:  Trends Cancer       Date:  2020-06-13

8.  Borax Pentahydrate and Disodium Pentaborate Decahydrate Are Candidates as Anti-leukemic Drug Components by Inducing Apoptosis and Changing Bax/Bcl-2 Ratio in HL-60 Cell Line.

Authors:  Tuğba Erkmen; Belgin Sert Serdar; Halil Ateş; Mehmet Korkmaz; Semra Koçtürk
Journal:  Biol Trace Elem Res       Date:  2021-06-29       Impact factor: 3.738

Review 9.  Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.

Authors:  Stelios Kasikis; Aaron Etra; John E Levine
Journal:  BioDrugs       Date:  2021-01       Impact factor: 5.807

10.  Bortezomib Inhibits Lung Fibrosis and Fibroblast Activation without Proteasome Inhibition.

Authors:  Loka Raghu Kumar Penke; Jennifer Speth; Scott Wettlaufer; Christina Draijer; Marc Peters-Golden
Journal:  Am J Respir Cell Mol Biol       Date:  2022-01       Impact factor: 7.748
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.